These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30897598)

  • 21. Oral hypoglycaemic agents.
    Borthwick LJ; Stowers JM
    Practitioner; 1979 Mar; 222(1329):358-66. PubMed ID: 450836
    [No Abstract]   [Full Text] [Related]  

  • 22. [Long term efficacy and tolerance of antidiabetic treatments. New data].
    Mirouze J
    Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493
    [No Abstract]   [Full Text] [Related]  

  • 23. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].
    Müller UA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):547. PubMed ID: 21351042
    [No Abstract]   [Full Text] [Related]  

  • 24. Sufficient increment of sulfonylurea without reintroduction of insulin ameliorates pubertal deterioration of glycaemic control in KCNJ11 neonatal diabetes treated with long-term sulfonylurea.
    Suzuki S; Mukai T; Kokumai T; Furuya A; Tanahashi Y; Azuma H
    Diabetologia; 2020 Aug; 63(8):1659-1661. PubMed ID: 32448915
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
    Riddle MC
    Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.
    Jackson JE; Bressler R
    Drugs; 1981 Oct; 22(4):295-320. PubMed ID: 7030708
    [No Abstract]   [Full Text] [Related]  

  • 27. Actual problems of the hypoglycaemic sulfonylureas.
    Káldor A
    Ther Hung; 1977; 25(2):47-50. PubMed ID: 898117
    [No Abstract]   [Full Text] [Related]  

  • 28. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study.
    Fuchs K
    Diabetologia; 1973 Sep; ():351-5. PubMed ID: 4772980
    [No Abstract]   [Full Text] [Related]  

  • 29. Familial occurrence of neonatal diabetes with duplications in chromosome 6q24: treatment with sulfonylurea and 40-yr follow-up.
    Søvik O; Aagenaes O; Eide SÅ; Mackay D; Temple IK; Molven A; Njølstad PR
    Pediatr Diabetes; 2012 Mar; 13(2):155-62. PubMed ID: 21518169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.
    Sperling MA
    N Engl J Med; 2006 Aug; 355(5):507-10. PubMed ID: 16885555
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of severe neonatal diabetes with very early sulfonylurea treatment.
    Marshall BA; Green RP; Wambach J; White NH; Remedi MS; Nichols CG
    Diabetes Care; 2015 Mar; 38(3):e38-9. PubMed ID: 25715421
    [No Abstract]   [Full Text] [Related]  

  • 33. Insulin and oral hypoglycemic agents.
    Price MJ
    Nurs Clin North Am; 1983 Dec; 18(4):687-706. PubMed ID: 6359069
    [No Abstract]   [Full Text] [Related]  

  • 34. [SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Nauck M; Del Prato S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S4-5. PubMed ID: 23529569
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical evaluation of glibornuride (glutril): a new oral antidiabetic drug.
    van der Merwe M; van Rooyen R
    S Afr Med J; 1973 Sep; 47(36):1638-42. PubMed ID: 4746966
    [No Abstract]   [Full Text] [Related]  

  • 36. [Recent development in the diabetes-therapy].
    Landgraf R; Dieterle C
    Internist (Berl); 1977 Oct; 18(10):509-19. PubMed ID: 412809
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral hypoglycaemic drugs: clinical pharmacology and therapeutic use.
    Stowers JM; Borthwick LJ
    Drugs; 1977 Jul; 14(1):41-56. PubMed ID: 328260
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities.
    Garcin L; Kariyawasam D; Busiah K; Fauret-Amsellem AL; Le Bourgeois F; Vaivre-Douret L; Cavé H; Polak M; Beltrand J
    Pediatr Diabetes; 2018 Jun; 19(4):663-669. PubMed ID: 29504184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical experience with the blood sugar reducing sulfonamide derivative glisoxepide].
    Petzoldt R; Riedesel G; Ramrath M; Grabs V; Haupt E; Schwedes U; Ewald W; Beyer J; Schöffling K
    Arzneimittelforschung; 1974 Mar; 24(0):429-32. PubMed ID: 4603399
    [No Abstract]   [Full Text] [Related]  

  • 40. Sulfonylurea-responsive diabetes in childhood.
    Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.